Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Response Biomed Corp RPBIF

Healthcare Diagnostics & Research
"Response Biomedical Corp is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets."


GREY:RPBIF - Post by User

Response Biomed Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by noleafcloveron Aug 12, 2011 10:47pm
346 Views
Post# 18938323

I think it's Great News.

I think it's Great News.Personally I don't feel like the company has made the strides it should have since Radvak left.  Good luck and good riddance Kaye!  I TRUST the new board knows what it's doing, and has a different and fresh perspective from Kaye.  I think we're finally headed in the right direction. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities